{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:49:53Z","timestamp":1788191393583,"version":"build-2803163510"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.euf.2018.09.009","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T19:44:12Z","timestamp":1540496652000},"page":"464-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Managing Toxicity of Intravesical Therapy"],"prefix":"10.1016","volume":"4","author":[{"given":"Joachim","family":"Mathes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Todenh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.euf.2018.09.009_bib0005","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin in Ta and T1 bladder cancer","author":"Shelley","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.euf.2018.09.009_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003231","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","author":"Shelley","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euf.2018.09.009_bib0015","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1086\/314064","article-title":"Efficacy and safety of bacille Calmette-Gu\u00e9rin immunotherapy in superficial bladder cancer","volume":"31","author":"Lamm","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.euf.2018.09.009_bib0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance Bacillus Calmette-Gu\u00e9rin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.09.009_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.09.009_bib0030","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus Calmette-Gu\u00e9rin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.09.009_bib0035","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.09.009_bib0040","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/21681805.2016.1236399","article-title":"Efficacy and safety of bladder hydrodistension for decreased bladder capacity induced by intravesical BCG therapy","volume":"50","author":"Numakura","year":"2016","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euf.2018.09.009_bib0045","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0022-5347(06)00264-3","article-title":"Complications of intravesical therapy for urothelial cancer of the bladder","volume":"175","author":"Koya","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.09.009_bib0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ucl.2013.01.005","article-title":"Side effects of perioperative intravesical treatment and treatment strategies for these side effects","volume":"40","author":"Griffin","year":"2013","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euf.2018.09.009_bib0055","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy\u2014associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.euf.2018.09.009_bib0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000052381","article-title":"BCG intravesical instillations: recommendations for side-effects management","volume":"37","author":"Rischmann","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.09.009_bib0065","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.urology.2004.11.053","article-title":"Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette Gu\u00e9rin-induced bladder contractures","volume":"65","author":"Nieder","year":"2005","journal-title":"Urology"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918302815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918302815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:48:05Z","timestamp":1762498085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456918302815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S2405456918302815"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2018.09.009","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Toxicity of Intravesical Therapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2018.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}